摘要
目的探讨HPV E6/E7 mRNA检测在分流HPV16/18阳性病人中的临床价值。方法收集2015年2月-2016年8月,在漯河医学高等专科学校第三附属医院进行常规新柏氏宫颈液基细胞学检测(TCT),且HPV16和/或18检测阳性,并且NILM患者在18个月内及TCT结果异常患者在6个月内进行阴道镜检的剩余TCT标本172例(未见上皮内细胞病变34例、ASCUS/LSIL:非典型鳞状上皮细胞轻度增生;HSIL/SCC:鳞状上皮内高度病变/鳞状细胞癌53例),其中具有组织学结果的患者135例。采用QuantiVirus^(TM)HPV E6/E7 mRNA技术检测剩余TCT标本中HPV E6/E7 mRNA表达水平。结果 E6/E7 mRNA在NILM组、ASCUS/LSIL组、HSIL/SCC组的阳性率分别为44.1%、65.9%、83.0%。HSIL/SCC组mRNA阳性率高于NILM组,差异有统计学意义(P<0.001),而其他2组间mRNA阳性率比较差异均无统计学意义(均P>0.016)。结论 E6/E7 mRNA将有助于HPV16和/或HPV18 DNA阳性患者的分流。
Objective To evaluate the HPV E6/E7 mRNA testing in the determination of women infected with human papillo- mavirus（HPV） 16/18. Methods Samples were collected from February 2015 to August 2016 in the Third Affiliated Hospital of Zhengzhou University for Thinprep cytology test（TCT） , and HPV16/18 were all detected; NILM patients in 18 months with TCT abnormal resuhs were conducted for colposcopy test within 6 months, and the TCT specimens of 172 cases were remained （including 34 cases of NILM, 85 cases of ASCUS/LSIL and 53 cases of HSIL/SCC） , in which 135 patients were underwent histological diagnosis. The residue of these TCT samples were conducted for HPV E6/E7 mRNA test by the method of Quanti- VirusTM HPV E6/E7 mRNA technology. Results The positive rates of E6/E7 mRNA in NILM, ASCUS/LSIL and HSIL/SCC were 44.1%, 65.9% and 83.0%, respectively. The positive rate of mRNA in HSIL/SCC were higher than that of NILM, with the difference statistically significant（ P 〈0.001 ） , but there was no statistical significance on the difference in the positive rate of mRNA between the two groups（P 〉0.016）. Conclusion HPV E6/E7 mRNA can be useful for the shunt of HPV16/18 or patients with positive HPV18 DNA.
作者
王富伟
魏爱婷
郭风涛
WANG Fu - wei WEI Ai - ting GUO Feng - tao(Clinical Laboratory, the Third Affiliated Hospital of Luohe Medical College, Luohe, Henan 462002, Chin)
出处
《中国卫生检验杂志》
CAS
2017年第10期1445-1447,共3页
Chinese Journal of Health Laboratory Technology
